Pfizer Net Worth
Pfizer Net Worth Breakdown | PFE |
Pfizer Net Worth Analysis
Pfizer's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pfizer's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pfizer's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pfizer's net worth analysis. One common approach is to calculate Pfizer's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pfizer's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pfizer's net worth. This approach calculates the present value of Pfizer's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pfizer's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pfizer's net worth. This involves comparing Pfizer's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pfizer's net worth relative to its peers.
Enterprise Value |
|
To determine if Pfizer is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pfizer's net worth research are outlined below:
| Pfizer Inc generated a negative expected return over the last 90 days | |
| About 68.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium |
Pfizer Quarterly Good Will |
|
Pfizer uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pfizer Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pfizer's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of May 2024 Upcoming Quarterly Report | View | |
| 6th of August 2024 Next Financial Report | View | |
| 31st of March 2024 Next Fiscal Quarter End | View | |
| 4th of February 2025 Next Fiscal Year End | View | |
| 31st of December 2023 Last Quarter Report | View | |
| 31st of December 2023 Last Financial Announcement | View |
Know Pfizer's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pfizer is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pfizer Inc backward and forwards among themselves. Pfizer's institutional investor refers to the entity that pools money to purchase Pfizer's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Capital World Investors | 2024-09-30 | 53.7 M | Bank Of America Corp | 2024-06-30 | 52.4 M | Amundi | 2024-06-30 | 50.2 M | Legal & General Group Plc | 2024-06-30 | 46.6 M | Bank Of New York Mellon Corp | 2024-06-30 | 41.9 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 38.1 M | Jpmorgan Chase & Co | 2024-06-30 | 37.2 M | Goldman Sachs Group Inc | 2024-06-30 | 34.9 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 33.4 M | Vanguard Group Inc | 2024-09-30 | 516.2 M | Blackrock Inc | 2024-06-30 | 424.4 M |
Follow Pfizer's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 146.04 B.Market Cap |
|
Project Pfizer's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
When accessing Pfizer's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pfizer's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pfizer's profitability and make more informed investment decisions.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Evaluate Pfizer's management efficiency
Pfizer Inc has Return on Asset of 0.0331 % which means that on every $100 spent on assets, it made $0.0331 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0454 %, implying that it generated $0.0454 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 15.82 | 16.61 | |
| Tangible Book Value Per Share | (7.69) | (7.31) | |
| Enterprise Value Over EBITDA | 24.11 | 15.62 | |
| Price Book Value Ratio | 1.83 | 1.73 | |
| Enterprise Value Multiple | 24.11 | 15.62 | |
| Price Fair Value | 1.83 | 1.73 | |
| Enterprise Value | 83.2 B | 87.3 B |
The strategic decisions made by Pfizer management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Enterprise Value Revenue 3.414 | Revenue 59.4 B | Quarterly Revenue Growth 0.312 | Revenue Per Share 10.493 | Return On Equity 0.0454 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pfizer insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
John Young over a year ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3 |
Pfizer Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 4th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 3rd of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Pfizer Earnings per Share Projection vs Actual
Pfizer Corporate Directors
| Helen Hobbs | Independent Director | Profile | |
| Shantanu Narayen | Lead Independent Director | Profile | |
| James Smith | Independent Director | Profile | |
| Susan DesmondHellmann | Independent Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.67 | Earnings Share 0.75 | Revenue Per Share 10.493 | Quarterly Revenue Growth 0.312 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.